Skip to main content

siremadlin

Generic: Siremadlin

siremadlin: 2 clinical trials tracked.

siremadlin evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about siremadlin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Acute Myeloid Leukemia
Clinical Trials (2)

A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Participants With Newly Diagnosed Unfit AML Presenting With High-risk Clinical Features

NCT05155709·Phase 1·NVS
Completed

Primary endpoint: Percentage of participants with Dose Limiting Toxicities (DLTs) as per investigator assessment reported during the first cycle (separately in Arm 1 & Arm 2)

Interventionalopen14 enrolledStarted 2022-05Completion 2024-0410 sites · Hong Kong, Hungary, Israel, Italy…Novartis Pharmaceuticals

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

NCT05180695·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: for dose escalation part: the Maximum tolerated dose (MTD) of HDM201 given in combination with a fixed dose of pazopanib.

Interventionalopen47 targetStarted 2022-04Completion 2027-025 sites · FranceCentre Leon Berard